Measles Vaccine
Expanding measles vaccination program in Zambia would save lives
Published in Vaccine Weekly, March 24th, 2004
According to a study from the United States, Canada, and Zambia, "The vaccination program in Zambia includes one dose of measles vaccine at nine months of age. The objective of this study was to compare the cost-effectiveness of the current one-dose measles vaccination program with an immunization schedule in which a second dose is provided either through routine health services or through supplemental immunization activities (SIAs). We simulated the expected cost and impact of the vaccination strategies for an annual cohort of 400,000 children, assuming 80% vaccination coverage in both...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2004-03-24)
More Articles from Vaccine Weekly
- HIV/AIDS Vaccine
SIV promoter exchange creates strain that protects against viral challenge - Cancer Vaccine
IL-12 enhances generation of tumor antigen-specific Th1CD4 T cells - Giardiasis Vaccine
Giardia intestinalis antigens stimulate a Th2 immune response - Malaria Vaccine
Cellular immunity induced by malaria vaccine, RTS,S/AS02, in adults in Gambia - Malaria Vaccine
Malaria-infected red blood cell antigens show promise as vaccine candidates - Anthrax Vaccine
Serological correlate of protection in rabbits for anthrax vaccine identified - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
